Margaret A Chang, MD, MS

Articles by Margaret A Chang, MD, MS

Anti-VEGF for RVO: The Gold Standard

ByCarl D. Regillo, MD, FACS,Margaret A Chang, MD, MS ,Dante J. Pieramici, MD,John W. Kitchens, MD

October 16th 2024

John W Kitchens, MD, bookends the discussion by highlighting the landscape of branch vein occlusion (BRVO) treatment options.

Faricimab for DME: Durability and Patient Outcomes

ByCarl D. Regillo, MD, FACS,Margaret A Chang, MD, MS ,Dante J. Pieramici, MD,John W. Kitchens, MD

October 16th 2024

Dante J Pieramici, MD, shifts the conversation to diabetic macular edema (DME) and the promising drying and anatomical results from an open-label long-term extension trial.

Faricimab for nAMD: Key Trial Highlights and Case Example

ByCarl D. Regillo, MD, FACS,Margaret A Chang, MD, MS ,Dante J. Pieramici, MD,John W. Kitchens, MD

October 16th 2024

Margaret A Chang, MD, MS, discusses efficacy and safety results of faricimab for neovascular age-related macular degeneration (nAMD) treatments.

Overview of Real-World Outcomes for nAMD, DME, and RVO Patients

ByCarl D. Regillo, MD, FACS,Margaret A Chang, MD, MS ,Dante J. Pieramici, MD,John W. Kitchens, MD

October 16th 2024

Carl D Regillo, MD, FACS, begins the discussion highlighting each disease state and the landscape of treatment.

Margaret A Chang, MD, MS

Articles by Margaret A Chang, MD, MS

Anti-VEGF for RVO: The Gold Standard

Faricimab for DME: Durability and Patient Outcomes

Faricimab for nAMD: Key Trial Highlights and Case Example

Overview of Real-World Outcomes for nAMD, DME, and RVO Patients

Latest Updated Articles

Trending on HCPLive

Machine Learning Model Predicts Type 2 Diabetes Risk Up To 10 Years Out

Diabetes Technology at a Turning Point: What’s New and What’s Next, With Rachael Sood, NP

ACCESS: Aleniglipron Achieves Up To 11.3% Weight Loss in Phase 2b Obesity Trial

Brief, Regular Movement Breaks Can Improve Cardiovascular Risk in T2D

5 Hepatology Headlines You Missed in May 2026